Orris

Management of stroke

Reading File
Finding Sources
Finding Sources
Searching PubMed

"ischemic stroke"[MeSH Terms] AND "management"[MeSH Terms]

Reading File
Reading File
Reading File
Searching PubMed

"stroke" AND "thrombolysis OR thrombectomy"

Reading File
Reading File
Finding Sources
Finding Sources
Reading File
Reading File
Finding Sources
Reading File
Reading File
Loading Image
Reading File
Reading File
I now have comprehensive content from multiple authoritative sources. Let me compile the complete, detailed answer.

Management of Stroke

Stroke is a medical emergency. Management differs fundamentally based on type: ischemic stroke (~80%) vs. hemorrhagic stroke (intracerebral hemorrhage ~15%, subarachnoid hemorrhage ~5%). A systematic approach covers acute stabilization, specific reperfusion/hemostatic therapies, prevention of complications, and secondary prevention.

1. Immediate Assessment and Stabilization

All patients with suspected stroke require urgent evaluation regardless of severity. Admission to a stroke unit or ICU is strongly preferred - specialized stroke unit care reduces mortality, hospital stay, discharge to nursing homes, and overall cost.
Airway, Breathing, Circulation (ABC):
  • Secure the airway; endotracheal intubation if GCS ≤8
  • Pulse oximetry/ABG; supplemental oxygen if SpO2 < 94%
  • Avoid hyperthermia (worsens ischemic outcome); treat fever aggressively
  • Cardiac monitoring for at least 48 hours (arrhythmias occur in 10-40%)
  • 12-lead ECG and troponin immediately (concomitant myocardial ischemia in 3-20%)
  • Monitor blood pressure continuously for 48-72 hours
Urgent Blood Tests:
  • CBC with differential and platelets
  • PT/INR, aPTT
  • Electrolytes, BUN, creatinine, glucose
  • Oxygen saturation
  • Consider toxicology screen, coagulation studies (factor V Leiden, protein C/S, antiphospholipid antibodies in younger patients)
Imaging:
  • Non-contrast CT head immediately - to exclude hemorrhage before thrombolysis
  • MRI DWI is more sensitive for acute ischemia (detects lacunar infarcts, posterior fossa strokes)
  • CTA/MRA for vascular imaging if thrombectomy is being considered
Neurological Assessment:
  • NIH Stroke Scale (NIHSS) - quantifies deficit and guides treatment eligibility
  • Bradley and Daroff's Neurology in Clinical Practice
  • Adams and Victor's Principles of Neurology, 12th Ed.

2. Acute Ischemic Stroke - Reperfusion Therapy

This is the cornerstone of acute ischemic stroke management. The guiding principle is "time is brain" - approximately 1.9 million neurons are lost per minute during a large hemispheric stroke.

A. Intravenous Thrombolysis (IV tPA)

Drug: Alteplase (standard) or Tenecteplase (newer; higher fibrin specificity, single bolus dose)
Dose of Alteplase: 0.9 mg/kg (max 90 mg); 10% as IV bolus, remaining 90% over 60 minutes
Time window: Within 4.5 hours of stroke onset (NINDS and ECASS-3 trials). Recent meta-analyses support extending this window beyond 4.5 hours in selected patients with perfusion-diffusion mismatch imaging.
Eligibility criteria:
  • Ischemic stroke causing measurable neurologic deficit
  • Symptom onset clearly within 4.5 hours
  • CT without hemorrhage or large hypodensity (>1/3 MCA territory)
  • Age ≥18
Absolute Contraindications:
  • Intracranial hemorrhage on imaging
  • SBP >185 mmHg or DBP >110 mmHg (that cannot be controlled)
  • Recent intracranial/intraspinal surgery, trauma, or stroke within 3 months
  • Active internal bleeding
  • Platelet count <100,000; INR >1.7; aPTT >40s; PT >15s
  • Blood glucose <50 mg/dL
  • Intracranial neoplasm, AVM, or aneurysm
  • Current use of GP IIb/IIIa inhibitors
  • Active infective endocarditis or suspected aortic arch dissection
BP management during tPA: Must be kept below 185/110 mmHg before and during infusion; below 180/105 mmHg for 24 hours after infusion.
Key risk: Symptomatic intracranial hemorrhage (~3-6%)
Recent evidence (2025): A meta-analysis in Neurology (PMID: 40674672) confirmed IV thrombolysis benefit in minor acute ischemic stroke. Another meta-analysis (Stroke, 2025, PMID: 39882605) supports thrombolysis beyond the 4.5-hour window in carefully selected patients with perfusion-diffusion mismatch.
  • Adams and Victor's Principles of Neurology, 12th Ed., pp. 820-822

B. Endovascular Thrombectomy (EVT / Mechanical Thrombectomy)

For large vessel occlusion (LVO) - distal ICA, proximal MCA (M1/M2), basilar artery.
Time windows:
WindowCriteria
0-6 hoursLarge vessel occlusion confirmed on CTA/MRA
6-24 hoursLarge vessel occlusion + perfusion-diffusion mismatch (DAWN, DEFUSE-3 trials)
Wake-up strokeDWI-FLAIR mismatch or perfusion imaging mismatch can be used to estimate "time last seen well"
Key principles:
  • Can be performed with or without preceding IV tPA (some trials show direct EVT non-inferior)
  • Stent retrievers (e.g., Solitaire, Trevo) and aspiration catheters are primary devices
  • Baseline ASPECTS score >6 generally favors good outcome
  • Large ischemic core (ASPECTS 0-5): A 2025 systematic review in Neurology (PMID: 40245349) found EVT still benefits patients with large ischemic cores; selection criteria are evolving
Basilar artery occlusion: EVT is beneficial but overall outcomes remain poor; superior to medical therapy alone based on recent RCTs (BASILAR, ATTENTION, BAOCHE trials).
  • Adams and Victor's Principles of Neurology, 12th Ed., pp. 820-826

3. Blood Pressure Management in Ischemic Stroke

BP management strategy depends on whether the patient receives tPA:
SituationTarget
No tPA, no large vessel occlusionDo NOT treat unless SBP >220 or DBP >120 mmHg
Before tPA administrationLower to <185/110 mmHg
Post-tPA (first 24 hours)Maintain <180/105 mmHg
Post-thrombectomyIndividualize; avoid hypotension
Optimal BP after ischemic stroke (without tPA) is 160-200 mmHg systolic - lower or higher pressures are associated with larger infarct volumes. Autoregulation is lost in ischemic tissue; aggressive lowering can worsen perfusion.
Agents used: IV labetalol (5-20 mg bolus), nicardipine infusion, or clevidipine.
  • Bradley and Daroff's Neurology in Clinical Practice; Textbook of Family Medicine 9e

4. Antiplatelet Therapy in Acute Ischemic Stroke

  • Aspirin 160-325 mg should be given within 24-48 hours of stroke onset (IST and CAST trials) in patients NOT receiving tPA (delay aspirin 24 hours after tPA)
  • Reduces stroke recurrence and mortality by ~1% at 4 weeks; modest but significant benefit
  • Dual antiplatelet therapy (DAPT): Aspirin + Clopidogrel for 21-90 days in minor stroke (NIHSS ≤3) or high-risk TIA (ABCD2 ≥4):
    • CHANCE trial (Chinese population): significant reduction in 90-day recurrent stroke
    • POINT trial (wider populations): confirmed efficacy; watch for systemic bleeding beyond 90 days
    • After 90 days, switch to single antiplatelet agent
  • Adams and Victor's Principles of Neurology, 12th Ed., p. 826

5. Acute Management of Hemorrhagic Stroke (ICH)

ICH accounts for 10-20% of strokes with 30-day mortality close to 50%. The primary causes are hypertension (72-81%), cerebral amyloid angiopathy, anticoagulant use, and AVM.
Immediate steps:
  1. Stabilize airway/vitals; intubate if GCS ≤8 (pretreat with fentanyl 2-3 mcg/kg to blunt ICP rise from laryngoscopy)
  2. Urgent CT head (defines location, size, presence of IVH, hydrocephalus)
  3. Labs: CBC, coagulation studies, toxicology, serum glucose (hyperglycemia associated with hematoma expansion)
  4. Neurosurgical consultation immediately
Blood Pressure Control in ICH:
  • Target SBP <140 mmHg is safe but may not improve outcomes (INTERACT-2, ATACH-2 trials)
  • Avoid SBP >180 mmHg; treat pharmacologically with IV nicardipine, labetalol
  • Maintain cerebral perfusion pressure 50-70 mmHg
Reversal of Coagulopathy (Hemostatic Therapy):
AnticoagulantReversal Agent
Warfarin (elevated INR)Vitamin K IV + 4-factor PCC (prothrombin complex concentrate)
HeparinProtamine sulfate
Dabigatran (DOAC)Idarucizumab (Praxbind)
Apixaban/RivaroxabanAndexanet alfa or 4-factor PCC
Hematoma expansion occurs in 28-38% of ICH presenting within 3 hours - early coagulopathy reversal is critical.
ICP Management:
  • Head of bed at 30-45 degrees
  • Mannitol 0.25-1 g/kg IV or 23.4% hypertonic saline for herniation
  • Hyperventilation as bridge
  • External ventricular drain (EVD) if hydrocephalus or intraventricular hemorrhage
Surgery for ICH:
  • Cerebellar hemorrhage >3 cm or with brainstem compression: surgical evacuation is recommended
  • Supratentorial ICH: Controversial; STICH and STICH-II trials showed no benefit for early surgery over medical management in most patients; surgery reserved for:
    • Superficial lobar hemorrhage with significant mass effect
    • Deteriorating neurological status
    • Refractory ICP
  • Bradley and Daroff's Neurology in Clinical Practice, pp. 1028-1030

6. Subarachnoid Hemorrhage (SAH)

  • Secure ruptured aneurysm: endovascular coiling (preferred) or surgical clipping
  • Nimodipine 60 mg every 4 hours for 21 days (reduces delayed cerebral ischemia from vasospasm)
  • Monitor for re-bleeding, hydrocephalus (EVD), and vasospasm (TCD monitoring)
  • Manage BP: avoid SBP >160 mmHg before aneurysm is secured; maintain euvolemia after

7. General Supportive Care (All Stroke Types)

IssueManagement
SwallowingNPO until formal assessment by speech pathology; NG tube feeding if dysphagia
Aspiration pneumoniaHOB >30°, frequent suctioning; dysphagia screen before oral intake
DVT/PE prophylaxisLMWH (enoxaparin 40 mg SC daily) or UFH 5000 units SC BID; IPC if anticoagulants contraindicated (PREVAIL, CLOTS-3 trials)
HyperglycemiaTarget glucose 140-180 mg/dL; avoid hypoglycemia (mimics stroke)
FeverTreat aggressively; paracetamol; cooling blankets
Urinary catheterAvoid unless essential; remove early to prevent urosepsis
Pressure soresFrequent repositioning, skin care, early mobility
DepressionScreen all patients (>25% develop post-stroke depression); SSRIs effective
SeizuresTreat clinically if occur; prophylactic AEDs not routinely indicated in ischemic stroke
Cerebral edemaPeak at 72-96 hours; mannitol, hypertonic saline; hemicraniectomy for malignant MCA syndrome (DESTINY trials)

8. Secondary Prevention

Antiplatelet Therapy

  • Aspirin monotherapy remains the backbone for non-cardioembolic ischemic stroke
  • Clopidogrel 75 mg daily is an alternative (slightly superior to aspirin in some studies)
  • Aspirin + dipyridamole (Aggrenox): comparable to clopidogrel
  • DAPT (aspirin + clopidogrel) for 21 days post minor stroke/TIA, then single agent

Anticoagulation

  • Atrial fibrillation: Direct oral anticoagulants (DOACs) are first-line - rivaroxaban, apixaban, dabigatran, edoxaban are superior to warfarin for stroke prevention with lower intracranial hemorrhage risk
  • Start anticoagulation after 2-14 days depending on infarct size (risk of hemorrhagic transformation)
  • Mechanical heart valve: Warfarin (INR 2.5-3.5) remains standard; DOACs contraindicated
  • Cardioembolic sources (non-AF): Evidence for anticoagulation varies; rivaroxaban not superior to aspirin in ESUS (embolic stroke of undetermined source)
  • Bridging with heparin: Not recommended for most patients; associated with higher bleeding risk without clear benefit (BRIDGE trial)

Lipid Management

  • High-intensity statin therapy (atorvastatin 40-80 mg): reduces recurrent stroke by ~2% over 5 years (SPARCL trial)
  • Target LDL <70 mg/dL for secondary stroke prevention

Blood Pressure

  • Long-term BP control is the most important modifiable risk factor
  • Target <130/80 mmHg for most stroke/TIA survivors
  • ACE inhibitors + thiazide diuretics have best evidence (PROGRESS trial)

Carotid Artery Disease

  • Symptomatic carotid stenosis ≥50%: Carotid endarterectomy (CEA) or carotid artery stenting (CAS) within 2 weeks of stroke/TIA (reduces 5-year risk of recurrent stroke by ~50% - NASCET trial)
  • Asymptomatic stenosis >70%: CEA considered in surgical-risk-appropriate patients

Lifestyle Modifications

  • Smoking cessation
  • Physical activity
  • Dietary changes (Mediterranean diet)
  • Alcohol moderation
  • Weight management, diabetes control

9. Rehabilitation

Rehabilitation begins as soon as the patient is medically stable:
  • Physiotherapy: Gait training, balance, motor recovery
  • Occupational therapy: ADLs, upper limb function
  • Speech therapy: Aphasia, dysarthria, dysphagia
  • Neuropsychology: Cognitive rehabilitation, depression
  • Stroke unit-based rehabilitation reduces dependency and death
  • Evidence supports early mobilization (within 24-48 hours) for most patients; very early intensive mobilization (within 24 hours) may be harmful (AVERT trial)

Summary Framework

STROKE
├── Ischemic (~80%)
│   ├── Acute: IV tPA (≤4.5h) ± Thrombectomy (LVO, ≤24h with mismatch)
│   ├── Supportive: BP management, aspirin, glucose/fever control
│   └── Secondary prevention: antiplatelet/anticoagulant, statin, antihypertensive, CEA
└── Hemorrhagic (~20%)
    ├── ICH: BP control (<140 SBP), coagulopathy reversal, ICP management, surgical EVD/evacuation
    └── SAH: Secure aneurysm (coiling/clipping), nimodipine, manage vasospasm
Sources:
  • Adams and Victor's Principles of Neurology, 12th Ed. (pp. 820-830)
  • Bradley and Daroff's Neurology in Clinical Practice (pp. 1028-1030, 1405-1408)
  • Textbook of Family Medicine, 9th Ed. (pp. 1223-1226)
  • Recent meta-analyses: EVT in large ischemic core (PMID 40245349, Neurology 2025); IV thrombolysis in minor stroke (PMID 40674672, Neurology 2025); thrombolysis beyond 4.5h (PMID 39882605, Stroke 2025)
This is a shared conversation. Sign in to Orris to start your own chat.